The Drug Science Podcast

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.  

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology. 

Depression

Bipolar disorder

Major depressive episode

Anhedonia

ICD-10

DSM-5

Atypical depression

Immuno-metabolic depression

SSRI

Rapid cycling bipolar disorder

Tricyclic antidepressants

Monoamine oxidase inhibitors (MAOIs)

Dopamine receptor D2

Cognitive Remediation Therapy

Institute of Psychiatry, Psychology & Neuroscience

CBT

Ketamine

Esketamine: Ketamine nasal spray 

Bioavailability

Psilocybin: From Serendipity to Credibility?

COMPASS Pathways

★ Support this podcast ★

Listen in to hear Robin’s valuable perspective on matters such as assisted death, private education and the difference between a debate and a conversation.

The Demon-Haunted World

The Infinite Monkey Cage

Assisted dying

Section 28

Peter Singer 

if…

Frankie Howerd

Amusing Ourselves to Death

★ Support this podcast ★

Coming from Canada, home to one of the most progressive drug addiction services in the world, Manisha was reporting for VICE News in their new documentary 'Beyond Fentanyl' which looks at how drugs like “benzos,” "dope” and “tranq” are ravaging North American communities and how U.S. policy affected the latest flood of synthetic street drugs.

Tune in to this week’s episode for a VICE  journalist’s perspective on drug policies around the world. 

Oxycodone

Heroin

Fentanyl

Benzodiazepines

Downer and upper drugs

Drug overdose

Noradrenaline

Lofexidine

Awakn clinic

“This Is Something That Changed My Life”: A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders

ibogaine

Psilocybin

Ayahuasca

DMT

Toad venom

5-MeO-DMT

Supervised injection sites

Naloxone

Bristol drug testing

The Loop

Mephedrone

Monkey dust

Bath Salts drug

oxycontin crisis

Cannabis

Beyond Fentanyl documentary 

★ Support this podcast ★

This week’s episode features Professor Bruce Alexander, a psychologist and professor emeritus from Vancouver, BC, Canada, author of two books about addiction: Peaceful Measures: Canada's Way Out of the War on Drugs and The Globalization of Addiction: A Study in Poverty of the Spirit.

Professor Alexander conducted a series of experiments into drug addiction known as the Rat Park experiments. Which brought into light the true complexity of addiction and the influence of our environment on how we use drugs and how they affect us. Listen to this episode to find out why the “demon drug myth” is extremely out of date with the scientific world and what we can do to debunk it.

Skin poppers

Heroin

Morphine

Demon drug myth

Ian Kershaw

Rat park

How permanent was Vietnam drug addiction

★ Support this podcast ★

This week’s episode features English television and radio presenter, and model Melanie Sykes.

Melanie is an advocate for medical cannabis use for childhood epilepsy and other chronic conditions. In 2021 she became an Ambassador in Medcan Support - a non-profit community interest company who provide free resources and educational material on medical cannabis, the endocannabinoid system and the positive outcomes cannabis treatment has had on so many people throughout the UK. With her support, she helps fight the stigma and raises other issues which are preventing access to the natural medicine.

Listen to this episode of the podcast to find out more about medical cannabis and also how an autism diagnosis at 51 can change your life! 

Don’t ‘Talk to FRANK’ but do check out the Frank magazine -> The Frank Magazine

Cannabis

Autism

Harry Thompson

ADHD

Neurodivergence

Medcan support

The Autistic Brain: Thinking Across the Spectrum

The Frank Magazine

Hemp

Weed the People

Epilepsy

Project Twenty21

William Broke O’Shaughnessy

★ Support this podcast ★